CAPItello-281 — Capivasertib plus Abiraterone and Prednisone in PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer

Phase 3 · 2025 · Prostate Cancer

Design

Randomized, double-blind, placebo-controlled trial of capivasertib plus abiraterone and prednisone versus placebo plus abiraterone and prednisone, with androgen deprivation therapy.

Population

PTEN-deficient metastatic hormone-sensitive (castration-sensitive) prostate cancer.

Primary Endpoint

radiographic progression-free survival (rPFS)

Key Result

Adding capivasertib to abiraterone and prednisone significantly improved radiographic progression-free survival in PTEN-deficient metastatic hormone-sensitive prostate cancer; overall survival follow-up is ongoing.

Guideline Impact

PTEN-deficient metastatic hormone-sensitive prostate cancer